(Q39841653)

English

Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

5

object named as

Len Neckers

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

author name string

Suiquan Wang

1

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Itai Pashtan

2

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Shinji Tsutsumi

3

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Wanping Xu

4

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

publication date

27 July 2009

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

2050-2056

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Physiologically-Based Pharmacokinetics and Molecular Pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and Its Active Metabolite in Tumor-Bearing Mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-dependent kinase-1.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regulation of lysophosphatidic acid-induced epidermal growth factor receptor transactivation and interleukin-8 secretion in human bronchial epithelial cells by protein kinase Cdelta, Lyn kinase, and matrix metalloproteinases

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dysregulation of Met receptor tyrosine kinase activity in invasive tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phorbol 12-myristate 13-acetate induces epidermal growth factor receptor transactivation via protein kinase Cdelta/c-Src pathways in glioblastoma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Protein kinase C is regulated in vivo by three functionally distinct phosphorylations

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces or

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hsp90 inhibitors as novel cancer chemotherapeutic agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Invasive growth: a MET-driven genetic programme for cancer and stem cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting Hsp90: small-molecule inhibitors and their clinical development

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

c-Met is a potentially new therapeutic target for treatment of human melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Signaling networks assembled by oncogenic EGFR and c-Met

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modulation of Akt kinase activity by binding to Hsp90

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Met, metastasis, motility and more

1 reference

https://pubmed.ncbi.nlm.nih.gov/19502802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.4161/CC.8.13.8861

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

PMC publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39841653&oldid=2091327131"